Second cancer risk in childhood cancer survivors treated with intensity‐modulated radiation therapy: An updated analysis of more than 10 years of follow‐up. Issue 5 (2nd March 2022)

• Record Type: Journal Article
• Authors: Tringale, Kathryn R.; Casey, Dana L.; Niyazov, Gregory; Lavery, Jessica A.; Moskowitz, Chaya; Friedman, Danielle N.; Wolden, Suzanne L.
• Is Part Of: Pediatric blood & cancer. Volume 69:Issue 5(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2022-03-02
• Subjects: IMRT -- pediatrics -- radiotherapy -- second malignancies -- survivorship; Tumors in children -- Periodicals; Blood -- Diseases -- Periodicals; Cancer in children -- Periodicals; 618.92
• DOI: 10.1002/pbc.29600
• Languages: English
• ISSNs: 1545-5009

Abstract

Abstract: Background: It is unclear how intensity‐modulated radiation therapy (IMRT) impacts long‐term risk of second malignant neoplasms (SMNs) in childhood cancer patients. Procedure: Patients aged ≤21 years treated with IMRT between 1998 and 2009 and who survived ≥5 years after IMRT were included. SMN site in relation to isodose level (IDL) of IMRT was evaluated. Standardized incidence ratios (SIR) and excess absolute risks (EAR) were calculated. Cumulative incidences were estimated with death as a competing risk. Results: Three‐hundred twenty‐five patients were included with median follow‐up of 11.2 years from IMRT (interquartile range: 9.4–14.0) among patients alive at the end of follow‐up. Two hundred (62%) patients had ≥10 years of follow‐up and 284 (87%) patients were alive at the time of analysis. Fifteen patients developed SMNs (11 solid, four hematologic). Median time from IMRT to solid SMN was 11.0 years (range: 6.8–19.2) with 10‐ and 15‐year cumulative incidences 1.8% (95% CI: 0.7–3.9) and 3.5% (95% CI: 1.4–7.5), respectively; SIR was 13.7 (95% CI: 6.9–24.6) and EAR was 2.8 per 1000 person‐years (95% CI: 1.0–4.6). Eight solid SMNs developed within the IMRT field (100% IDL [ n = 5], 80% IDL [ n = 1], 50% IDL [ n = 1], 40% IDL [ n = 1]), one within the 70%–80% IDL of a conventional field, one was out‐of‐field, and one could not be determined. Conclusions: With median follow‐up of >10 years, many solid SMNs after IMRT in childhood cancer survivors develop in the high‐dose region. These data serve as a foundation for comparison with other modalities of radiation treatment (e.g., proton therapy).